Mouse IgG1 ELISA Kit
$350.00 – $450.00
SPECIES | Mouse |
---|---|
Sample Type | Serum, plasma, cell culture supernatant, and other biological samples |
Sample Volume | 50 μL |
Sensitivity | 0.02 ng/mL |
Range | 3.13 ng/mL – 200 ng/mL |
Assay Time | 3.5 h |
Recovery | 96% – 108% |
Average Recovery | 1.01 |
Sample Type | Serum, plasma, cell culture supernatant, and other biological samples |
---|---|
Sample Volume | 50 μL |
Sensitivity | 0.02 ng/mL |
Range | 3.13 ng/mL – 200 ng/mL |
Assay Time | 3.5 h |
Recovery | 96% – 108% |
Average Recovery | 1.01 |
Intra Precision | 3.2%-8.9% |
Inter-Precision | 1.5% – 8.6% |
Platform | ELISA |
Plate | Detachable 96-well plate |
Size | 96T/48T |
Storage | If the reagent kit is unopened, it should be stored at 4℃. However, if it has been opened, the standard solution should be stored at -20℃, while the other components should be stored at 4℃. |
Delivery | 4℃ blue ice transportation |
Components | 96-well polystyrene enzyme-linked immunosorbent assay (ELISA) plate coated with anti-IgG1 monoclonal antibody Mouse IgG1 freeze-dried standard IgG1 detect Antibody Standard Diluent Assay Buffer(10×) Substrate TMB Stop Solution Washing Buffer(20×) Sealing Film |
Assay Principle | This kit utilizes the double antibody sandwich enzyme-linked immunosorbent assay (ELISA) detection technique.Specific anti-mouse IgG1 antibodies are precoated on a high-affinity ELISA plate. Standard samples, test samples, and the detection antibody labeled with horseradish peroxidase are added to the wells of the ELISA plate. After incubation, IgG1 present in the samples binds to the solid-phase antibodies and the detection antibodies. After washing, a colorimetric substrate, TMB, is added and the plate is incubated in the dark for color development. The intensity of the color reaction is directly proportional to the concentration of IgG1 in the samples.A stop solution is added to terminate the reaction, and the absorbance value is measured at a wavelength of 450 nm (with a reference wavelength range of 570-630 nm). |
5.7
Protective efficacy of Toxoplasma gondii GRA12 or GRA7 recombinant proteins encapsulated in PLGA nanoparticles against acute Toxoplasma gondii infection in mice
Frontiers in Cellular and Infection Microbiology
17.1
Radiotherapy-Triggered In Situ Tumor Vaccination Boosts Checkpoint Blockaded Immune Response via Antigen-Capturing Nanoadjuvants
ACS Nano
5.578
Formulation and Evaluation of Lipidized Imiquimod as an Effective Adjuvant
ACS Infectious Diseases
5.6
The mechanism underlying the inverse proportion between serum IgE concentration and Stat3 transcriptional activity depends on Stat3 mutation type
INTERNATIONAL IMMUNOPHARMACOLOGY
6.688
The G allele of SNP rs3922 reduces the binding affinity between IGF2BP3 and CXCR5 correlating with a lower antibody production
EUROPEAN JOURNAL OF IMMUNOLOGY
Allergic Reaction
Cardiovascular Disease (Hypertension & Atherosclerosis & Acute Myocardial Infarction & Coronary Heart Disease)
Eye Diseases (Glaucoma & Cataract)
Lung Disease (Asthma & COPD)
Multiple Sclerosis
Nervous System Diseases (Depression & Alzheimer & Epilepsy & Parkinson)
Obesity Diabetes
Osteoarthrosis & Rheumatoid Arthritis
Osteoporosis
Sepsis
Systemic Lupus Erythematosus
Transplantation
Tumor Marker